Elisabetta Bonzano: Improved efficacy outcomes in early-stage TNBC neoadjuvant ICI therapy
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:
“Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer A Systematic Review and Meta-Analysis.
Neoadjuvant Immunotherapy—From Trials to Practice
Authors: Elizabeth A. Mittendorf, Sara M. Tolaney
In this meta-analysis involving 5114 patients neoadjuvant ICI therapy was associated with improved efficacy outcomes in early-stage TNBC and PD-L1+ HR+/ERBB2- tumors with an acceptable safety profile. However, in triple-negative breast cancer, no benefit was observed with adjuvant ICI in patients with pCR or residual disease. Given the financial and toxicity costs associated with ICIs, future research should prioritize identifying patients most likely to benefit from the addition of ICIs to neoadjuvant chemotherapy.”
Source: Elisabetta Bonzano/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023